Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents

Investigative Radiology

Volumn 31, Issue 12, 1996, Pages 739-742

  Puttagunta, N Rao ^b   Gibby, Wendell A ^a   Smith, G Tracy ^b  

^a UTAH VALLEY REGIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

assays, serum and urine; Contrast agents, magnetic resonance; human transmetallation; in vivo stability; zinc depletion

Indexed keywords

CONTRAST MEDIUM; COPPER; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIDOL; ZINC;

ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG METABOLISM; DRUG STABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030449238     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199612000-00001     Document Type: Article

References (16)

1. Hals P, Hogset A. Disposition of gadolinium after high and low doses of gadolinium chloride to mice. In: Works in progress: Society of magnetic resonance in medicine 1990. Berkeley, CA: Society of Magnetic Resonance in Medicine, 1990.
2. Rocklage SM, Worah D, Kim S. Metal ion release from paramagnetic chelates: What is tolerable? Magn Reson Med 1991; 22:216-221.
3. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: Relationship to chemical characteristics. Magn Reson Imaging 1992; 10:641-648.
4. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372-380.
5. Kasokat T, Urich K. Quantification of dechelation of gadopentetate dimeglumine in rats. Arzneim-Forsch/Drug Res 1992;42:869-876.
6. Molgo J, Pozo ED, Banos JE, Anguit-Petit D. Changes of quantal transmitter release caused by gadolinium ions at the frog neuromuscular junction. Br J Pharmacol 1991;104:133-138.
7. Biagi BA, Enyeart JJ. Gadolinium blocks low- and high-threshold calcium currents in pituitary cells. Am J Physiol 1990;259(cell physiol 28):C515-C520.
8. Nordenbo AM, Somnier FE. Acute deterioration of myasthenia gravis after intravenous administration of gadolinium DTPA. The Lancet 1992;340:1168. Letter to the Editor.
9. Hattner RS, White DL. Gallium-67/stable gadolinium antagonism MRI contrast agent markedly alters the normal biodistribution of Gallium-67. J Nucl Med 1990;31:1844-1846.
10. Gibby WA, Puttagunta NR. Comparative transmetallation kinetics and thermodynamic stability studies of Gd DTPA-Bisglucosamide. J Magn Reson Imaging 1994;4(p):71-72.
11. 3 in rats. In: Proceedings of the Society of Magnetic Resonance in Medicine 1994. Berkeley, CA: Society of Magnetic Research in Medicine, 1994:916.
12. Thomas J, Chisomm JJ Jr. Lead, zinc, copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of lead-poisoned children. J Pharmacol Exp Ther 1986;239:829-835.
13. Slobodien MJ, Brodsky A, Ke CH, Horm I. Removal of zinc from humans by DTPA chelation therapy. Health Physics 1973; 24:327-330.
14. Hustvedt SO, Holtz E, Normann PT, Harpur ES. Comparative tolerance of gadodiamide injection in rats and monkeys. In: Proceedings of the Society of Magnetic Resonance in Medicine 1993. Berkeley, CA: Society of Magnetic Resonance in Medicine, 1993:792.
15. Report of the task group on reference man, International Commission. Radiological protection. Oxford, NY: Pergamon Press, 1975. Publication 23.
16. Jackson GE, Michael JB. Metal ion speciation in blood plasma: gallium-67-citrate and MRI contrast agents. J Nucl Med 1996; 37:379-386.